PATENT CLAIM ANALYSIS

Application Number: 15750143
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "588000"]

Abstract:
The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.

Claim (Index 22):
The method of  claim 11 , wherein the macular thickness is reduced by 100 \u03bcm after 3 months of treatment.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 88.0
- Lexical Diversity: 1.51948
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13102768', '14029603', '15471506', '13940370', '14972560']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7494395504343597
- 35 USC 102 Novelty (BERT): 0.5103802736853588
- Combined Prediction Score: 0.7255336227594597
- Mean Citation Score: 177.97768
- Max Citation Score: 183.01375
- Similarity Product: 99.04758365966376

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test